LONDON, UK: RTW Venture Fund Limited’s portfolio company Ventyx Biosciences Inc. announced pricing of an upsized $151.5 million initial public offering (IPO) and admission to trade on Nasdaq Global Market under ticker “VTYX”.
Ventyx is a clinical-stage biopharmaceutical company advancing a pipeline of novel small molecule therapeutics with a best-in-class potential for patients with inflammatory and autoimmune diseases.
Ventyx’s pipeline programs include: (1) a selective allosteric TYK2 inhibitor for a broad range of immunological disorders, (2) a tissue selective S1P1R modulator for inflammatory bowel disease (IBD), and (3) a preclinical NLRP3 inhibitor program.
Prior to IPO, the Company, together with other funds managed by RTW Investments, LP, participated in Ventyx’s $114 million financing round in March 2021.
Ventyx’s IPO raised $151.5 million by offering c. 9.5 million shares at $16.00 per share. On the first day of trading, Ventyx’s share price increased by 31.4% to close at $21.02 per share.
Stephanie Sirota, Chief Business Officer of the Investment Manager and Director of the Company, said: “We are excited about Ventyx’s successful IPO and look forward to supporting the company in its efforts to develop innovative therapeutics for patients with inflammatory and autoimmune diseases”.